v3.25.2
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive Loss
Beginning Balance (in shares) at Dec. 31, 2023   35,521      
Beginning Balance at Dec. 31, 2023 $ 1,981,420 $ 355 $ 16,760 $ 2,114,765 $ (150,460)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 79,965     79,965  
Other comprehensive income (loss)          
Cumulative translation adjustment (11,433)       (11,433)
Issuance of common stock in connection with:          
Exercise of options (in shares)   106      
Exercise of options 3,898 $ 1 3,897    
Restricted share grants, less net settled shares (in shares)   70      
Restricted share grants, less net settled shares (8,306) $ 1 (8,307)    
Share-based compensation 8,812   8,812    
Ending Balance (in shares) at Mar. 31, 2024   35,697      
Ending Balance at Mar. 31, 2024 2,054,356 $ 357 21,162 2,194,730 (161,893)
Beginning Balance (in shares) at Dec. 31, 2023   35,521      
Beginning Balance at Dec. 31, 2023 1,981,420 $ 355 16,760 2,114,765 (150,460)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 163,912        
Ending Balance (in shares) at Jun. 30, 2024   35,902      
Ending Balance at Jun. 30, 2024 2,149,380 $ 359 33,955 2,278,677 (163,611)
Beginning Balance (in shares) at Mar. 31, 2024   35,697      
Beginning Balance at Mar. 31, 2024 2,054,356 $ 357 21,162 2,194,730 (161,893)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 83,947     83,947  
Other comprehensive income (loss)          
Cumulative translation adjustment (1,718)       (1,718)
Issuance of common stock in connection with:          
Exercise of options (in shares)   180      
Exercise of options 6,716 $ 2 6,714    
Restricted share grants, less net settled shares (in shares)   25      
Restricted share grants, less net settled shares (3,210)   (3,210)    
Share-based compensation 9,289   9,289    
Ending Balance (in shares) at Jun. 30, 2024   35,902      
Ending Balance at Jun. 30, 2024 $ 2,149,380 $ 359 33,955 2,278,677 (163,611)
Beginning Balance (in shares) at Dec. 31, 2024 35,913 35,913      
Beginning Balance at Dec. 31, 2024 $ 2,258,290 $ 359 39,650 2,394,853 (176,572)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 61,824     61,824  
Other comprehensive income (loss)          
Cumulative translation adjustment 14,574       14,574
Issuance of common stock in connection with:          
Exercise of options (in shares)   2      
Exercise of options 80   80    
Restricted share grants, less net settled shares (in shares)   67      
Restricted share grants, less net settled shares (7,207) $ 1 (7,208)    
Purchase and retirement of common stock, including excise tax (in shares)   (1,127)      
Purchase and retirement of common stock, including excise tax (187,676) $ (11) (187,665)    
Share-based compensation 9,753   9,753    
Reclassification of negative additional paid-in capital 0   145,390 (145,390)  
Ending Balance (in shares) at Mar. 31, 2025   34,855      
Ending Balance at Mar. 31, 2025 $ 2,149,638 $ 349 0 2,311,287 (161,998)
Beginning Balance (in shares) at Dec. 31, 2024 35,913 35,913      
Beginning Balance at Dec. 31, 2024 $ 2,258,290 $ 359 39,650 2,394,853 (176,572)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income $ 133,522        
Ending Balance (in shares) at Jun. 30, 2025 32,727 32,727      
Ending Balance at Jun. 30, 2025 $ 1,899,881 $ 327 0 2,027,779 (128,225)
Beginning Balance (in shares) at Mar. 31, 2025   34,855      
Beginning Balance at Mar. 31, 2025 2,149,638 $ 349 0 2,311,287 (161,998)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 71,698     71,698  
Other comprehensive income (loss)          
Cumulative translation adjustment 33,773       33,773
Issuance of common stock in connection with:          
Exercise of options (in shares)   18      
Exercise of options 697   697    
Restricted share grants, less net settled shares (in shares)   46      
Restricted share grants, less net settled shares (7,603)   (7,603)    
Purchase and retirement of common stock, including excise tax (in shares)   (2,192)      
Purchase and retirement of common stock, including excise tax (358,240) $ (22) (358,218)    
Share-based compensation 9,918   9,918    
Reclassification of negative additional paid-in capital $ 0   355,206 (355,206)  
Ending Balance (in shares) at Jun. 30, 2025 32,727 32,727      
Ending Balance at Jun. 30, 2025 $ 1,899,881 $ 327 $ 0 $ 2,027,779 $ (128,225)